Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
55.96
+2.98 (5.62%)
Jul 30, 2026, 4:00 PM EDT - Market closed

Vaxcyte Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-1,089-923.68-569.55-468.04-232.26-103.67
Net Income
-946.53-766.63-463.93-402.27-223.49-100.08
Earnings Per Share
-6.88-5.63-3.80-4.14-3.44-1.93
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,7371,5611,7471,080931.38245.97
Total Debt
116.3117.4871.1129.2217.9416.78
Net Cash (Debt)
1,6211,4431,6761,051913.44229.19
Net Cash Growth
2.30%-13.88%59.48%15.06%298.55%-40.65%
Net Cash Per Share
11.8310.6113.7410.8214.084.41

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-769.93-655.58-452.63-296.79-170.6-121.39
Capital Expenditures
-45.02-56.97-119.16-67.88-5.84-6.56
Free Cash Flow
-814.94-712.55-571.79-364.67-176.44-127.95
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.